Rznomics Joins Lilly Gateway Labs in San Diego
South Korean biotechnology firm Rznomics Inc. announced its participation in Eli Lilly and Company's Gateway Labs initiative in San Diego, California. The collaboration aims to accelerate the development of RNA-based gene therapies.
Rznomics Inc., a South Korean biopharmaceutical company specializing in RNA-based gene therapies, has joined Eli Lilly and Company's Gateway Labs (LGL) in San Diego, California. The move is intended to accelerate the development of Rznomics' therapeutic candidates.
The company, listed on KOSDAQ (476830), focuses on developing treatments leveraging RNA technology. Gateway Labs provides emerging biotechnology companies with access to Lilly's expertise, resources, and facilities to advance their drug development programs.
By joining Gateway Labs, Rznomics gains a strategic foothold within San Diego's significant biotechnology ecosystem. This positions the company to benefit from the region's network of innovation and collaborative opportunities in drug discovery and development.
Rznomics has not disclosed specific research projects that will be prioritized under the collaboration. The partnership is part of the company's broader strategy to bring novel RNA-based therapies to patients.